RAS mutation

Every cell in the body contains blueprints called genes. Part of these blueprints determines when a cell is allowed to divide and when it should stop. Three of these blueprints carry the name RAS, more precisely KRAS, NRAS, and HRAS. If one of them is altered by a copying error, this is called a RAS mutation. The protein produced from the blueprint then works incorrectly: it continuously signals to the cell that it should divide. This constant growth signal can give rise to a tumor.

The most common cancer gene of all

RAS mutations are among the most frequently found alterations in tumors. Estimates suggest that around a quarter of all human cancers carry such a mutation. They are found particularly often in the pancreas, the colon, and the lungs. In pancreatic cancer, depending on the study, this figure exceeds 90 percent of cases.

The mutation is also important because it influences the choice of treatment. There are medications that only work in colorectal cancer if the RAS gene is unaltered. For this reason, the tumor is tested in the laboratory for this mutation before treatment begins. If the test is positive, patient and doctor are spared a treatment that would not help.

For decades, RAS was considered untargetable. The protein has a smooth surface to which active substances barely adhere. Only in the past few years have approved medications become available against a specific variant called KRAS G12C. This breakthrough has made the field interesting again for pharmaceutical companies and investors.

A switch that’s stuck

The RAS protein functions like a switch with two positions. In one position, it continues to send the signal to grow, in the other it stays silent. Normally, it switches itself off again after a short time. A mutation often changes only a single building block of the protein. After that, it can no longer switch off.

The result is a chain: RAS passes the signal on to other proteins inside the cell, which in turn pass it on to the cell nucleus. There, genes are activated that start cell division. Because the first switch is stuck, the entire chain runs continuously. The cell divides even though nothing from outside is prompting it to anymore.

A common misconception is that such mutations are inherited from one’s parents. The vast majority of RAS mutations arise only during the course of life, in a single body cell. Triggers can include chance events during cell division, tobacco smoke, or other harmful influences. Offspring do not inherit this alteration.

From tissue sample to stock market announcement

In everyday medical practice, the term comes up when examining tumor tissue. A laboratory reads out the genetic code of the tumor and specifically searches for known error sites. The finding then appears in the medical report, for example as KRAS G12D. Such codes specify exactly which building block was swapped at which position.

In business news, RAS is encountered mainly in reports about pharmaceutical companies. Approvals, study results, and acquisitions related to RAS medications regularly move stock prices. The market is considered large because so many types of tumors are affected.

The term also appears in reports about artificial intelligence in medicine. Programs search through vast amounts of data for molecules that could bind to the hard-to-target RAS protein. Such methods are intended to shorten the search for new active substances. Whether they deliver on this promise will only become clear through clinical trials in humans.